Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.

Aung M Tun,Seth M. Maliske,Yucai Wang,Matthew J. Maurer,Ivana N. Micallef,David J. Inwards,Luis F. Porrata,Allison C. Rosenthal,Mohamed A. Kharfan-Dabaja,Jacob J. Orme,Brian K. Link,James R. Cerhan,Carrie A. Thompson,Thomas M. Habermann,Thomas E. Witzig,Stephen M. Ansell,Grzegorz S. Nowakowski,Umar Farooq,Patrick B. Johnston

Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.

2021

Aung M Tun
Seth M. Maliske
Yucai Wang
Matthew J. Maurer
Ivana N. Micallef
David J. Inwards
Luis F. Porrata
Allison C. Rosenthal
Mohamed A. Kharfan-Dabaja
Jacob J. Orme
Brian K. Link
James R. Cerhan
Carrie A. Thompson
Thomas M. Habermann
Thomas E. Witzig
Stephen M. Ansell
Grzegorz S. Nowakowski
Umar Farooq
Patrick B. Johnston

7522Background: Patients with newly diagnoseddiffuse large B-cell lymphoma (DLBCL) who achieve event-free survival at 24 months (EFS24) following immunochemotherapy (IC) have excellent overall surv...

Keywords:

Medicine
Internal medicine
Oncology
Lymphoma
Stem cell
Refractory Diffuse Large B-Cell Lymphoma
Progression-free survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations